Effectiveness and Safety of Advanced Combination Treatment in Patients With Refractory Inflammatory Bowel Disease or Concomitant Immune-Mediated Disease or Extraintestinal Manifestations: A Multicenter Canadian Study
Virginia Solitano(Western University), Vipul Jairath(Western University), Çharles N. Bernstein(University of Manitoba), Greg Rosenfeld(British Columbia Centre on Substance Use), John K. Marshall(McMaster University), Talat Bessissow(Montreal General Hospital), Jeffrey D. McCurdy(University of Ottawa), Yvette Leung(University of Calgary), Frank Hoentjen(Radboud University Nijmegen), Neeraj Narula(McMaster University), Ropo Ebenezer Ogunsakin(Western University), Remo Panaccione, Christopher Ma(University of Calgary), Mohammed Alahmari(Population Health Research Institute), Sanjay K. Murthy(University of Ottawa), Raquel Milgrom(Mount Sinai Hospital), Brian Bressler(University of British Columbia), Mark S. Silverberg(Sinai Health System), Yuhong Yuan(McMaster University), L van Lierop(University of Alberta)
Cited by 10
Related Papers
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k